| Human Diabetes miRNA PCR Array: MIHS-115Z |
|
| The Human Diabetes miScript miRNA PCR Array profiles the expression of 84 miRNAs experimentally identified and/or bioinformatically predicted to epigenetically regulate diabetes-related biological processes. During food consumption, insulin release from pancreatic beta cells activates insulin signaling and cellular uptake of glucose, resulting in synthesis and storage of carbohydrates and lipids. Insulin-resistant individuals are vulnerable to multiple pathophysiologies, including development of non-insulin dependent diabetes mellitus (NIDDM), or type 2 diabetes. Insulin resistance is a key link between obesity and NIDDM, and may be caused by dysregulation of the complex signaling between liver, adipose tissue, skeletal muscle, and pancreatic beta cells. Many miRNAs are differentially regulated in one or more tissues (liver, adipose, skeletal muscle, and pancreatic beta islets) during insulin resistance and diabetes progression. Since each miRNA may regulate hundreds of genes, one miRNA could alter the expression of a different set of genes in each tissue, depending on the gene’s tissue-specific expression. This array includes miRNAs differentially regulated in specific tissues as observed by experimental research on insulin resistance and diabetes progression. These experimentally identified miRNAs were also analyzed bioinformatically to determine if they may regulate common diabetes-related genes. The same bioinformatics process was also used to suggest potential novel diabetes-related miRNAs to include on the array. A set of controls present on each array enables data analysis using the ΔΔCT method of relative quantification, assessment of reverse transcription performance, and assessment of PCR performance. Using SYBR Green real-time PCR, the expression of a focused panel of miRNAs related to type 2 diabetes and insulin resistance can be easily and reliably analyzed with this miScript miRNA PCR Array.
miScript miRNA PCR Arrays are intended for molecular biology applications. This product is not intended for the diagnosis, prevention or treatment of a disease.
96-well, 384-well ( 4 x 96 ), and Rotor-Disc 100 formats are available. |
|
|
|
|
Differentially Expressed in all 4 Diabetes Target Tissues: let-7f-5p, miR-107, miR-130a-3p, miR-133a, miR-193a-3p, miR-206, miR-27a-3p, miR-296-5p, miR-376a-3p.
Differentially Expressed in 3 Diabetes Target Tissues:
Liver, Adipose Tissue, and Skeletal Muscle: miR-1, miR-125a-5p, miR-125b-5p, miR-127-3p, miR-148a-3p, miR-150-5p, miR-194-5p, miR-199a-5p, miR-26a-5p, miR-29a-3p, miR-29b-3p, miR-29c-3p, miR-301a-3p, miR-324-3p, miR-324-5p, miR-335-5p.
Liver, Adipose Tissue, and Pancreatic Beta Cells: let-7i-5p, miR-103a-3p, miR-135b-5p, miR-143-3p, miR-146a-5p, miR-15b-5p, miR-185-5p, miR-190a, miR-195-5p , miR-196b-5p, miR-200a-3p, miR-204-5p, miR-212-3p, miR-214-3p, miR-21-5p, miR-330-5p, miR-34a-5p, miR-365a-3p, miR-375, miR-377-3p, miR-382-5p, miR-433.
Liver, Skeletal Muscle, and Pancreatic Beta Cells: miR-152, miR-183-5p.
Adipose Tissue, Skeletal Muscle, and Pancreatic Beta Cells: let-7e-5p, miR-450a-5p, miR-7-5p.
Differentially Expressed in 2 Diabetes Target Tissues:
Liver and Adipose Tissue: miR-129-2-3p, miR-133b, miR-19a-3p, miR-34c-5p, miR-370, miR-381-3p, miR-99b-5p.
Liver and Skeletal Muscle: miR-451a.
Liver and Pancreatic Beta Cells: miR-380-5p.
Adipose Tissue and Skeletal Muscle: miR-129-5p, miR-23a-3p, miR-23b-3p, miR-24-3p, miR-26b-5p, miR-27b-3p, miR-30a-5p, miR-30c-5p, miR-361-5p, miR-424-5p, miR-490-3p, miR-542-3p.
Adipose Tissue and Pancreatic Beta Cells: miR-130b-3p, miR-184, miR-320b, miR-96-5p.
Skeletal Muscle and Pancreatic Beta Cells: miR-126-5p.
Novel miRNAs Predicted to Regulate Diabetes-Related Genes: miR-3121-3p, miR-4699-3p, miR-4729, miR-506-3p, miR-4458, miR-4500. |
